Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "fc coins satin al Visit Buyfc26coins.com for latest FC 26 coins news..XeZ3"

Looking for quality documents?
external link icon
Repligen Reports Third Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance
Reports record quarterly revenue of $94.1 million with strong margin expansion
Overall revenue grew 35% year-over-year, with organic growth of 31% Raises revenue guidance to $ 348 -$ 352 million and overall revenue growth to 29%-30% for full year 2020, representing 23 %- 24 % organic growth Completes acquisition of Non-Metallic Solutions and an nounces a greement to a cquire b ioprocess s ystems i nnovator ARTeSYN Biosolutions WALTHAM, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter of 2020. Provided in this press release are financial highlights for the three- and nine- month periods ended September 30, 2020, updates to our financial guidance for the fiscal year 2020 and access information for today’s webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “We are pleased with our momentum
external link icon
Repligen Reports Second Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance
Reports record quarterly revenue of $87.5 million
Overall revenue grew 24% year-over-year, with organic growth of 19% Raises revenue guidance to $332-$340 million for full year 2020, representing 18%-21% organic growth Completes acquisition of silicone molding and tubing manufacturer Engineered Molding Technology WALTHAM, Mass., July 30, 2020 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter of 2020. Provided in this press release are financial highlights for the three- and six- month periods ended June 30, 2020, updates to our financial guidance for the fiscal year 2020 and access information for today’s webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “I’m pleased to report that the company delivered outstanding financial performance during the second quarter as we continue to focus on keeping all our
external link icon
Repligen Reports First Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance
Reports record quarterly revenue of $76.1 million
Overall revenue grew 25% year-over-year, with organic growth of 16% Strong order load through first four months WALTHAM, Mass., May 06, 2020 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter ended March 31, 2020. Provided in this press release are financial highlights for the quarter, updates to our financial guidance for the year 2020 and access information for today’s webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “I’m really pleased with our flexibility and performance during the first quarter, while adapting to the challenging economic environment. We exceeded our financial goals, reporting record quarterly revenue and organic growth of 16% backed by strong order demand. The story of the quarter was the continued momentum at gene therapy accounts and
external link icon
Repligen Reports First Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance
Reports first quarter revenue of $60.6 million, representing 35% year-over-year growth and 37% organic growth Raises revenue guidance to $235-$241 million for full year 2019, representing 22%-25% organic growth  Enters agreement to acquire analytics leader C Technologies Closes follow-on offering for net proceeds of $190 million WALTHAM, Mass., May 09, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter of 2019. Provided in this press release are financial highlights for the three-month period ended March 31, 2019, recent business highlights, updated financial guidance for the fiscal year 2019, and access information for today's webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “I’m extremely pleased with our accomplishments and performance during the first quarter. We executed on our business and
external link icon
Repligen Announces Conference Call of First Quarter Fiscal Year 2011 Results Thursday, August 5th 10:00 a.m. EDT
external link icon
Repligen Announces Conference Call of First Quarter Fiscal Year 2010 Results Thursday, August 6th, 10:00 a.m. EDT
external link icon
Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2009 Results Thursday, June 11th, 10:00 a.m. EDT
external link icon
Repligen to Present at the Cowen & Company 29th Annual Healthcare Conference, Monday, March 16th, 2:25 p.m. EDT
external link icon
Repligen Announces Conference Call of Second Quarter Fiscal Year 2011 Results Tuesday, November 2nd, 3:00 p.m. EDT
external link icon
Repligen to Present at the Rodman & Renshaw Annual Global Investment Conference Monday, September 13th, 12:05 p.m. EDT
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support